Dihexa

Overview

Dihexa is a small synthetic peptide derived from angiotensin IV, originally developed by researchers at Washington State University as an investigational candidate for neurodegenerative conditions such as Alzheimer’s disease. Structural modifications to the parent peptide were designed to improve its stability and its ability to reach the brain, making it a more tractable compound for laboratory study.

It is most often discussed as a highly experimental cognitive enhancer, or nootropic. In animal models it has been reported to support synaptic connectivity and memory-related behaviors, and in some assays it showed neurotrophic activity at very low concentrations.

Human evidence for Dihexa itself is very limited. It is not approved by any major regulator for therapeutic use and is sold for research purposes only. A separate phosphate prodrug based on Dihexa, known as fosgonimeton, has been studied in clinical trials, but that is a distinct compound.

How it works

In preclinical research, Dihexa is described as a potentiator of hepatocyte growth factor (HGF) signaling at its receptor, c-Met (also written MET). This HGF/MET pathway has been linked in laboratory studies to synaptogenesis — the formation of new connections between neurons — and to dendritic and synaptic remodeling thought to underlie learning and memory.

The precise mechanism in humans is not established, and some of the foundational biochemistry publications in this area have since been subject to a notice of concern or retraction. The mechanistic picture should therefore be treated as emerging and preliminary.

Reported benefits

• Support for synaptic connectivity and neuronal remodeling (preclinical data)
• Improved performance on memory and learning tasks in animal models
• Neurotrophic (nerve-supporting) activity studied in cell-based assays

These are reported and studied effects, not guaranteed outcomes, and they come largely from laboratory and animal research rather than controlled human trials.

Considerations & side effects

Because well-controlled human trials of Dihexa are lacking, its safety profile in people is not characterized. Some short-duration animal studies reported no obvious toxicity, but because the HGF/MET pathway is involved in cell growth, questions about long-term effects remain open and unanswered in humans.

Product purity varies widely in the research-chemical market, and Dihexa is a highly experimental compound with limited independent verification of quality. It is not a substitute for evaluation and treatment by a qualified clinician.